Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Dr Stefan Ryser joins Telik

This article was originally published in Scrip

Executive Summary

Dr Stefan Ryser has been appointed to the newly created position of senior vice-president of corporate strategy at Telik (US). He has more than 20 years' executive and investment experience in the biotechnology and pharmaceutical industries, including 10 years as an independent Telik director. Dr Ryser most recently served as founding and managing partner of Bear Stearns Health Innoventures.

You may also be interested in...



QUOTED. 6 August 2020. Department of Health and Social Care.

The UK Department of Health and Social Care recently asked medical device and pharmaceutical companies to establish contingency measures in case of supply problems post-Brexit.

J&J’s COVID Vaccine Contract With US Bucks Trend Of Increasingly Lucrative Deals

PDUFA Needs More Than 300 Additional FTEs, New US FDA Capacity Planning Formula Says

But the agency chose to fund only a small fraction of them, in part because of its hiring ability, and in part because all those employees would have cost an additional $98.7m in user fee revenue.

Topics

Related Companies

UsernamePublicRestriction

Register

LL1127945

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel